Shroom & Magic MushroomPsychedelic Neuroscience

January 5, 2023by Dr.Jake Donaldson0

Psychedelic Neuroscience

This article discusses the neurobiological effects of psychedelic substances, the alterations in brain activity that ensue, and the incorporation of conventional ideas. As any scientist who has experienced it is aware, science is still in the early stages of comprehending psychedelic chemical mechanisms and considerably further from understanding the psychedelic state.

Introduction: The Classification of Psychedelics

After decades of constrained research due to the legal status of psychedelics, the area of psychedelic neuroscience has recently seen a revival. There are discrepancies in the literature on terminology, classification, content, and effects of various psychedelics because this discipline is still relatively new.

  • The word “psychedelic” refers to substances that reveal the mind. These substances have exceptional anti-amnesic properties and can “make conscious” things that were previously unconscious due to changes in brain “state,” but there is also mounting evidence that these substances also influence epigenetic mechanisms. This encourages the use of psychedelics for traditional therapeutic purposes to treat ancestral trauma. Along with explanations of these mechanisms, recommendations for additional study are given.

The current classification of psychedelics into classic and atypical psychedelics, which each have unique therapeutic potentials and capacities to elicit potent acute experiences and long-lasting changes in neurobiology through concurrent activation of several neuro-modulatory systems, is based on their neuro-receptor affinities. Atypical/non-traditional/non-classical psychedelics and classic psychedelics are included in the currently recognized classification of psychedelics.

  • Tryptamines such as 5-methoxy-dimethytryptamine (5-MeO-DMT), which can be produced synthetically but is also found in Bufo alvarius toad venom and several plants including Anadenanthera peregrina, a derivative commonly known as Amazonian yopo snuffs), and N,N-dimethyltryptamine (N,N-DMT; found in ayahuasca (LSD; derived from lysergic acid extracted from ergot fungus). Atypical psychedelics can be further divided into dissociative psychedelics (N-methyl-d-aspartate receptor-NMDA antagonists), such as phencyclidine (PCP; original synthesis was toward anesthetic), ketamine (an amnesic surgical anesthetic), and ibogaine (derived from Apocynaceae family of plants), as well as cannabinoid agonists (such as 9-tetrahydr.

Current Issue Within the Field of Neuroscience

The problem of inconsistent results, probably brought on by the scant study, is problematic in the field, maybe more so than in other fields. One study found that the 5HT2A receptor antagonist, ketanserin, blocked the effect of noribogaine on structural plasticity yet both ibogaine and noribogaine failed to induce head-shake response in rats, a behavior that is seen to be comparable to hallucinations in humans and mediated by 5HT2A activation. This finding supports the skepticism that the low 5HT2A affinity of ibogaine has any functional relevance.

  • The literature on 5-MeO-DMT is another instance where there is ambiguity. While research suggests that ayahuasca contains a significant amount of N,N-DMT, 5-MeO-DMT concentration is either nonexistent or low in most brews, and the psychedelic effects of ayahuasca are said to be similar to those of 5-MeO-DMT to a very small extent.

 

  • The research on cannabis is thus maybe the best illustration of contrasting psychedelic research. According to the evidence we’ve looked at, it’s unclear whether cannabis consumption has any negative consequences on human mental health or cognition. The functional human neuroimaging investigations also produced a wide range of inconsistent findings. It is true that this is a young and developing field of study, and further investigation is needed to learn more about the many psychedelic substances, their active ingredients, and their neurological effects.

Neurobiology of Psychedelics: Psychiatric Conditions

Unlike any currently accessible medication, traditional psychedelics and dissociative psychedelics are known to offer rapid onset antidepressant and anti-addictive effects. Randomized clinical control studies have verified that traditional psychedelics have antidepressant and anxiolytic effects on people.

  • Ketamine also has well-documented impacts on human addiction and depression due to its role as an NMDA antagonist. Ibogaine has shown strong anti-addictive potential in pre-clinical research, and clinical trials to ascertain its efficacy in thorough human investigations are currently in the early phases.

In addition to their quick onset, psychedelics are also known to have long-lasting effects, such as modifications to mood and cognitive function. These effects are thought to be caused by their particular receptor affinities, which impact neurotransmission through neuro-modulatory systems and subsequently serve to modulate brain activity, or neuroplasticity.

  • According to reports, these long-term effects support cell survival, act as a neuroprotective, and alter the brain’s neuroimmune systems. Epigenetic alterations and changes in gene expression have been related to the mechanisms behind these long-lasting neuro-modulatory changes.
  • These previously unstudied effects of psychedelic drugs could potentially lead to the development of the next generation of neurotherapeutics, which could treat disorders that are currently untreatable, such as depression and addiction, with lowered pharmacological risks.
  • It is also acknowledged that the abuse potential of traditional psychedelics is extremely low, and it is hypothesized that activating 5HT2C receptors limits their potential for addiction and that their therapeutic effects are mediated by acute activation of 5HT2C receptors followed by sustained downregulation of 5HT2A and 5HT1A receptors.

There has been little research on the role of 5HT7 activation by psychedelics, but it has been suggested that it may play a role in the classic psychedelic anti-addiction properties, specifically 5-MeO-DMT in alcohol use disorder.

Psychedelic Neurobiology

It is also acknowledged that traditional psychedelics have a very low potential for abuse. It is hypothesized that traditional psychedelics’ therapeutic effects are mediated by acute activation of 5HT2C receptors followed by sustained downregulation of 5HT2A and 5HT1A receptors, which limits their potential for addiction.

  • However, it has been claimed that 5HT7 activation by psychedelics, specifically 5-MeO-DMT in alcohol use disorder, may contribute to the traditional psychedelic anti-addiction characteristics. The study of the intricate mechanisms by which traditional psychedelics exert their antidepressant and anti-addiction effects via the serotonergic system continues to advance.

The numerous traditional and atypical psychedelics produce varied psychedelic states, which may be used to distinguish between the precise neuroreceptor-mind interactions. Numerous genetic variations occur in the population for these neuro-modulatory systems, which have distinct genes that code for their neuroreceptors.

  • Consequently, variation in the neuroreceptor-mind interactions has even more promise for psychiatric neuro-genomics research since it will reveal how unique genetic diversity in the neuro-modulatory systems causes various psychedelic states and alterations in neurobiology.

Most research has focused on the role of the serotonergic system in the psychedelic experience, and this has led to new understandings of the neurochemical mechanisms causing modifications in brain network activity and perfusion. Numerous neurological (such as epilepsy) and mental (such as depression) disorders include serotonin.

  • Serotonin receptors can alter the excitability of brain networks by directly or indirectly depolarizing or hyperpolarizing neurons by altering the ionic conductance and/or concentration within the cells.

For instance, psilocin generates brain signal increases in the olfactory and limbic areas and brain signal decreases in the somatosensory and motor cortices, according to pharmacological magnetic resonance imaging (phMRI) in rats. Rats’ frontal cortex oscillations and cortical activity are disrupted by 5-MeO-DMT, and the alternating activity in the frontal and visual areas that is linked with psychedelic effects is observed.

  • A psilocybin investigation found that while hemodynamic responsiveness was improved, local field potentials to sensory inputs were diminished. These findings call into question our understanding of the nature of the differential neuronal versus hemodynamic activity and how it interacts to produce the psychedelic experience. They also support a shift in the brain’s “state.”

There have been few studies on human brain imaging, and the neurophysiological theories that underlie them are mostly conjectural, but the results are intriguing and require more research. For instance, a study using LSD and functional magnetic resonance imaging (fMRI) discovered increased hemodynamic activity in brain regions with high levels of 5HT2A receptors. The authors came to the general conclusion that this indicated increased functional connectivity and that the increased activity caused ego dissolution.

  • A subsequent psilocybin fMRI investigation discovered lower hemodynamic activity in the thalamus, anterior, and posterior cingulate cortices, with the decreased anterior cingulate activity correlating with the psychedelic experience.

Psychedelic & Psychosis

13.4% of the 21,967 participants in a population study that looked into psychedelic use in Norway in 2013 reported using them at some point in their lives. The study found no significant correlation between psychedelic use and outcomes related to mental health, and in some cases, it was linked to lower rates of mental health issues. When psychosis does occur and persist, the use of psychedelics like cannabis is thought to be a contributing factor.

For instance, certain naturally occurring genetic variants interact with cannabis and other environmental factors (such as stress) to raise the chance of developing psychosis. As a result, psychedelics do not cause psychosis or psychotic disorder on their own because a person needs to be genetically predisposed or have a higher risk of becoming psychotic in order to do so.

Future Implications

Psychedelic “microdosing,” as it is known in the area, requires more study. There is only one human study in the literature that showed that microdosing psilocybin had a positive impact on creativity, despite the fact that Murnane indicated that sub-psychedelic doses of psychedelic chemicals have been proven to help with some diseases or ailments. The profession may benefit greatly from more controlled studies in this area.

Combination psychedelic therapy is another topic that needs more investigation. Psychedelics are frequently combined by traditional practitioners, who have been doing so for many years. Researchers have put up a proposal that suggests sequential administration of 5-MeO-DMT and ibogaine might be more successful in treating addiction than sequential administration of either substance alone.

  • Since this is the first study of its kind evaluating combined psychedelic therapy, more research is required to fully understand the pharmacology of poly-psychedelics. The combined neurotransmitter profile of the two substances would probably have an enhanced effect when used in combination.

Furthermore, there are changes in the brain’s “state” as reported by neuroimaging and electrophysiological research, and scientists speculate that this may be related to the decoupling of some as-yet-unidentified brain networks.

Last but not least, it has been suggested that a key topic for future research will be the identification of non-psychedelic substances with similar serotonergic and glutamatergic receptor affinities as psychedelics, with an eye toward potential anti-neuroinflammatory characteristics.

Dr.Jake Donaldson

Leave a Reply

Your email address will not be published. Required fields are marked *

ADDRESS: British Columbia, Canada
EMAIL: [email protected]
WORKING DAYS/HOURS: 7 Days a Week / 8:00 AM – 4:00 PM PST

All rights reserved 2020

0